Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
World J Urol. 2019 Dec;37(12):2721-2726. doi: 10.1007/s00345-018-02618-1. Epub 2019 Mar 13.
Macrophages are a major cell type that can infiltrate solid tumors and exhibit distinct phenotypes in different tumor microenvironments. This study investigates the prognostic value of tumor-infiltrated CD163+ macrophages in patients with T1 high-grade (T1HG) bladder cancer.
CD163+ macrophages were assessed by immunohistochemistry in 94 T1HG bladder cancer samples. Kaplan-Meier analyses and Cox proportional hazards' regression models were applied to evaluate recurrence-free survival, progression-free survival and disease-specific survival.
With a median follow-up of 60 months, 37 (39.4%) patients experienced disease recurrence, 14 (14.9%) progression, 11 (11.7%) disease-specific mortality. High CD163+ macrophages were associated with higher risk of disease recurrence and progression (P < 0.05, for both). In multivariate Cox proportional hazards regression analysis, high CD163+ macrophages were a significant negative predictor of recurrence-free survival, progression-free survival and disease-specific survival (P < 0.05 for all).
CD163+ macrophages are a poor prognostic factor in T1HG bladder cancer. This finding provide the ground for further testing it in predicting the outcome of this challenging disease.
巨噬细胞是一种主要的细胞类型，可浸润实体肿瘤，并在不同的肿瘤微环境中表现出不同的表型。本研究旨在探讨浸润性肿瘤的 CD163+巨噬细胞在 T1 高级别（T1HG）膀胱癌患者中的预后价值。
采用免疫组织化学法检测 94 例 T1HG 膀胱癌样本中的 CD163+巨噬细胞。采用 Kaplan-Meier 分析和 Cox 比例风险回归模型评估无复发生存率、无进展生存率和疾病特异性生存率。
中位随访 60 个月后，37 例（39.4%）患者出现疾病复发，14 例（14.9%）患者出现进展，11 例（11.7%）患者出现疾病特异性死亡。高 CD163+巨噬细胞与更高的疾病复发和进展风险相关（均 P<0.05）。多因素 Cox 比例风险回归分析显示，高 CD163+巨噬细胞是无复发生存率、无进展生存率和疾病特异性生存率的显著负预测因子（均 P<0.05）。
CD163+巨噬细胞是 T1HG 膀胱癌的不良预后因素。这一发现为进一步研究其在预测这种具有挑战性的疾病结局中的应用提供了依据。
